# NCT04221945 (NCT04221945)

> Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04221945
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Uterine Cervical Neoplasms
- Interventions: Pembrolizumab; Placebo for pembrolizumab; Cisplatin; External Beam Radiotherapy (EBRT); Brachytherapy
- Enrollment: 1060
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 39
- X threads: 38
- YouTube: 37

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04221945

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04221945", "email": "<work email>"}; the inbox owner confirms by the emailed link.